18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
US10815200B2 · kind B2 · utility
4Cited by
1References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 8, 2018 |
| Grant date | Oct 27, 2020 |
| Priority date | — |
| Expiry date | Mar 8, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.